ObjectiveTo evaluate the clinical and biochemical effects of long-acting testosterone undecanoate injections in men with prostate cancer treated with brachytherapy, as the use of testosterone therapy (TTh) in men with prostate cancer is highly controversial, with limited published safety data, particularly after brachytherapy treatment. Patients and MethodsIn all, 20 men treated with brachytherapy for prostate cancer received TTh for symptoms of testosterone deficiency from February 2005 to August 2013. Symptoms of testosterone deficiency included low libido, erectile dysfunction, and fatigue. The mode of TTh was long-acting testosterone undecanoate injections in all cases. Sexual function was assessed by Sexual Health Inventory for Men (SHIM) questionnaire. Serum PSA and testosterone concentrations were recorded monthly for 3 months, then every 3 months for the first year, every 6 months for the second year, and annually then after. ResultsThe mean (range) age was 62 (49-74) years and the mean (range) serum PSA level at the time of prostate cancer diagnosis was 6.2 (2-11.5) ng/mL. The Gleason score was 2 + 3 in one patient, 3 + 3 in 15 patients, 3 + 4 in three patients and 4 + 4 in one patient. In all, 15 men were stage T1c and five were T2a. The mean (range) baseline total testosterone concentration was 343 (200-592) ng/dL, and 6.9 (2.1-9.7) ng/dL for free testosterone. The mean SHIM scores improved with treatment from 16.1 at baseline to 22.1 with TTh (P = 0.002). There was a decrease in mean PSA level from baseline of 0.7 ng/mL before initiation of TTh to 0.1 ng/mL at last follow-up (P < 0.001), with a median (range) follow-up of 31 (12-48) months. There were no cases of prostate cancer progression or recurrence. ConclusionsWith a median of 31-months follow-up, long-acting testosterone injections in men with prostate cancer treated with brachytherapy produced significant clinical benefits. There were no cases of rising serum PSA, prostate cancer progression or recurrence.

No abstract

La fístula vesicovaginal (FVV) es una enfermedad frecuente en países no desarrollados y afecta la calidad de vida de mujeres en edad media, siendo la causa más habitual la histerectomía previa. Las técnicas quirúrgicas disponibles para su reparación presentan resultados variables. Objetivos: Presentar nuestra experiencia en la reparación de FVV por vía laparoscópica con abordaje retrovesical, en una serie consecutiva de 6 pacientes. Método: análisis prospectivo descriptivo de 6 pacientes sometidos a reparación laparoscópica retrovesical de FVV supratrigonales secundarias a histerectomías. Resultados: El tiempo operatorio promedio fue de 191 minutos. Ningún paciente requirió transfusiones y el tiempo de hospitalización promedio fue de 2,5 días. No se presentaron complicaciones ni recidivas, con un seguimiento promedio de 15 meses. Conclusión: La reparación laparoscópica de FVV mediante técnica retrovesical es una técnica segura, poco invasiva y reproducible en manos entrenadas, que podría convertirse en la técnica de elección a futuro. De acuerdo a nuestra revisión, esta comunicación es la primera serie de reparación laparoscópica de FVV publicada en Chile.